{"id":644087,"date":"2023-03-23T18:28:01","date_gmt":"2023-03-23T18:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=644087"},"modified":"2023-03-23T18:28:01","modified_gmt":"2023-03-23T18:28:01","slug":"80-active-companies-working-to-develop-100-pipeline-therapies-for-type-1-diabetes-treatment","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/80-active-companies-working-to-develop-100-pipeline-therapies-for-type-1-diabetes-treatment_644087.html","title":{"rendered":"80+ Active Companies working to Develop 100+ Pipeline Therapies for Type 1 Diabetes Treatment"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1679565290.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"80+ Active Companies working to Develop 100+ Pipeline Therapies for Type 1 Diabetes Treatment   \" src=\"https:\/\/www.abnewswire.com\/uploads\/1679565290.png\" alt=\"80+ Active Companies working to Develop 100+ Pipeline Therapies for Type 1 Diabetes Treatment   \" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s, &#8220;Type 1 Diabetes Pipeline Insight 2023&#8221; report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including Type 1 Diabetes clinical trials and nonclinical stage products. It also covers the Type 1 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key takeaways from the Type 1 Diabetes Pipeline Report<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&#8217;s Type 1 Diabetes Pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Type 1 Diabetes treatment.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The leading Type 1 Diabetes Companies such as Landos Biopharma, Zealand Pharma, Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy, SQZ Biotech, Enthera, and others are evaluating new type 1 diabetes drugs to improve the treatment landscape.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The promising Type 1 Diabetes Therapies in various stages of development such as LABP 111, TTP 399, Teplizumab, Emricasan, VX 880, Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine, ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin, Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301, Dasiglucagon, SQZ TAC research program, Ent001, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The Type 1 Diabetes Companies and academics are working to assess challenges and seek opportunities that could influence R&amp;D Type 1 Diabetes. The Type 1 Diabetes pipeline therapies under development are focused on novel approaches to treat\/improve Type 1 Diabetes.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Explore more about the latest breakthroughs in the Type 1 Diabetes Treatment Landscape @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Type 1 Diabetes Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. Type 1 diabetes mellitus (T1DM) is an autoimmune disease that leads to the destruction of insulin-producing pancreatic beta cells. Insulin is an essential anabolic hormone that exerts multiple effects on glucose, lipid, protein, and mineral metabolism, as well as growth.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Recent Developmental Activities in Type 1 Diabetes Treatment Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; In July 2022, Vertex Pharmaceuticals announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; In June 2022, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold placed on the Phase I\/II clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemia awareness and severe hypoglycemia.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; In April 2022, AVM Biotechnology received Small Business Innovation Research (SBIR) award of $1.6m from the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) to study its small molecule, AVM0703, for reversing Type 1 diabetes (T1D). The latest grant will permit the company to carry out further research into using AVM0703 as a single agent and as a combination treatment for reversing recent onset and established T1D.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; In May 2022, Sernova and Evotec are pleased to announce an exclusive global strategic partnership to develop a best-in-class cell therapy treatment for people living with insulin-dependent diabetes. The partnership provides Sernova a global exclusive option to license Evotec&#8217;s iPSC-based beta cells for use in treating both type 1 and type 2 diabetes. In addition to entering into the collaboration agreement, Evotec has made a strategic equity investment of &euro;15M and will make a further investment of &euro;5M.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; In March 2022, Jaguar Gene Therapy announced Samsung Ventures, an investment corporation established to promote the development of new technologies, and the JDRF T1D Fund, a venture philanthropy fund devoted to finding and funding the best cure-oriented therapies for Type 1 diabetes (T1D), have invested in the company.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; In January 2022, Remedium Bio announced it has entered into a Sponsored Research Agreement with the University of Massachusetts Boston to complete pre-clinical efficacy studies on Type 1 and Type 2 Diabetes pipeline candidates. The collaboration to evaluate platform technology for the treatment of Diabetes, with translational potential to the broader Remedium pipeline of single-injection potentially disease-modifying gene therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Emerging Drugs<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; Teplizumab: Prevention Bio<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; Emricasan: Histogen<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; VX-880: Vertex Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapy set to grab substantial Type 1 Diabetes Pipeline Landscape @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Type 1 Diabetes Ongoing Clinical Trial Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Pipeline Therapeutics Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 80+ key companies which are developing therapies for Type 1 Diabetes. The companies which have their Type 1 Diabetes drug candidates in the most advanced stage, i.e preregistration include Provention Bio.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Type 1 Diabetes Pipeline Report covers around 100+ products under different phases of clinical development-<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; Late-stage products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; Mid-stage products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; Early-stage product (Phase I) along with the details of<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; Pre-clinical and Discovery stage candidates<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; Discontinued &amp; Inactive candidates<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Know which Type 1 Diabetes Treatment Drugs are expected to score the touchdown first @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Type 1 Diabetes Treatment Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Type 1 Diabetes Pipeline Report<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Type 1 Diabetes Companies- Landos Biopharma, Zealand Pharma, Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy, SQZ Biotech, Enthera, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Type 1 Diabetes Pipeline Therapies- LABP 111, TTP 399, Teplizumab, Emricasan, VX 880, Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine, ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin, Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301, Dasiglucagon, SQZ TAC research program, Ent001, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Type 1 Diabetes Segmentation: Phases, Molecule Type, Mechanism of Action, Route of Administration, Product Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Type 1 Diabetes: Overview<\/p>\n<p style=\"text-align: justify;\">4. Type 1 Diabetes Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Type 1 Diabetes Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Type 1 Diabetes- DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">7. Late Stage Products (Preregistration)<\/p>\n<p style=\"text-align: justify;\">8. Teplizumab: Provention Bio<\/p>\n<p style=\"text-align: justify;\">9. Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">10. TTP 399: Novo Nordisk<\/p>\n<p style=\"text-align: justify;\">11. Early Stage Products (Phase I\/II)<\/p>\n<p style=\"text-align: justify;\">12. SBP 101: Takeda Oncology<\/p>\n<p style=\"text-align: justify;\">13. Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">14. Eflornithine oral: Panbela Therapeutics<\/p>\n<p style=\"text-align: justify;\">15. Inactive Products<\/p>\n<p style=\"text-align: justify;\">16. Type 1 Diabetes Key Companies<\/p>\n<p style=\"text-align: justify;\">17. Type 1 Diabetes Key Products<\/p>\n<p style=\"text-align: justify;\">18. Type 1 Diabetes- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">19. Type 1 Diabetes- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">20. Type 1 Diabetes- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">21. Type 1 Diabetes Analyst Views<\/p>\n<p style=\"text-align: justify;\">22. Type 1 Diabetes Key Companies<\/p>\n<p style=\"text-align: justify;\">23. Appendix<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information on the Type 1 Diabetes Pipeline Therapeutics, reach out <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Type 1 Diabetes Market Drivers and Barriers<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_111587.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=80-active-companies-working-to-develop-100-pipeline-therapies-for-type-1-diabetes-treatment\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432,  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> United States<br \/><strong>Country:<\/strong> India<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=80-active-companies-working-to-develop-100-pipeline-therapies-for-type-1-diabetes-treatment\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&#8217;s, &#8220;Type 1 Diabetes Pipeline Insight 2023&#8221; report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including Type 1 Diabetes clinical trials &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/80-active-companies-working-to-develop-100-pipeline-therapies-for-type-1-diabetes-treatment_644087.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-644087","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/644087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=644087"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/644087\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=644087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=644087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=644087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}